Celebrating a new era of diagnostic innovation

Join Beckman Coulter Diagnostics as it enters an exciting era of clinical innovation. The company's new President, Kevin O’Reilly, shares his vision for advancing Beckman Coulter Diagnostics with groundbreaking technologies like the award-winning DxI 9000.

Discover how Beckman Coulter is revolutionizing clinical diagnostics through enhanced reliability, automation, and workflow efficiency. Learn about the company's commitment to making significant clinical impacts, including the development of a blood-based Alzheimer's biomarker test.

This video was filmed at ADLM 2024 and is shared as part of the global CLINICAL24 conversation. .